Catabasis Pharmaceuticals to Present at Upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference
Presentation details are as follows:
Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis, will present “Global Phase 3 PolarisDMD Trial for Edasalonexent, an Oral NF-kB Inhibitor in Boys with DMD”
Presentation held during the poster session on
Thursday, April 4, 2019, from 10:00am to 11:15am GMT.
Richard Finkel, M.D., Chief, Division of Neurology, Department of Pediatricsat Nemours Children’s Health System and a Principal Investigator for the MoveDMD and PolarisDMD studies, will present “MoveDMD Phase 2 Data Supports Design of PolarisDMD, a Phase 3 Study of Edasalonexent, a Novel NF-kB Inhibitor”
Presentation held during the Poster Reception on
Tuesday, April 16, 2019, in the Exhibit Hall from 6:00pm– 8:00pm EDT.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small molecule that is being developed as a potential foundational therapy for all patients affected by DMD, regardless of their underlying mutation. Edasalonexent inhibits NF-kB, which is a key link between loss of dystrophin and disease progression in DMD. NF-kB has a fundamental role in skeletal and cardiac muscle disease in DMD. We are currently enrolling our global Phase 3 PolarisDMD trial to evaluate the efficacy and safety of edasalonexent for registration purposes. In our MoveDMD Phase 2 trial and open-label extension, we observed that edasalonexent preserved muscle function and substantially slowed disease progression compared to rates of change in a control period, and significantly improved biomarkers of muscle health and inflammation. Edasalonexent continues to be dosed in the open-label extension of the MoveDMD trial. The
Catabasis Pharmaceuticals, Inc.
T: (617) 349-1971